Clinical Trials Logo

Clinical Trial Summary

This study is A Randomized, Double-blind, Placebo-controlled, Phase II Optimal Dose-finding Study to Determine the Safety and Efficacy of DWP450 in Subjects with Benign Masseteric Hypertrophy


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03369990
Study type Interventional
Source Daewoong Pharmaceutical Co. LTD.
Contact
Status Not yet recruiting
Phase Phase 2
Start date December 2017
Completion date October 2018

See also
  Status Clinical Trial Phase
Completed NCT04443244 - Evaluate the Safety and Efficacy of Botulax® in Subjects With Benign Masseteric Hypertrophy Phase 2
Completed NCT04294251 - Efficacy and Safety of DWP450 in Subjects With Benign Masseteric Hypertrophy Phase 3
Recruiting NCT05964257 - To Evaluate the Efficacy and Safety of LIZTOX in Subjects With Benign Masseteric Hypertrophy Phase 3